

# Systemic Idiopathic Juvenile Arthritis Treatment- EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/S7988792B7FEN.html>

Date: February 2018

Pages: 148

Price: US\$ 3,480.00 (Single User License)

ID: S7988792B7FEN

## Abstracts

### Report Summary

Systemic Idiopathic Juvenile Arthritis Treatment-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Systemic Idiopathic Juvenile Arthritis Treatment industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Systemic Idiopathic Juvenile Arthritis Treatment 2013-2017, and development forecast 2018-2023

Main market players of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA, with company and product introduction, position in the Systemic Idiopathic Juvenile Arthritis Treatment market

Market status and development trend of Systemic Idiopathic Juvenile Arthritis Treatment by types and applications

Cost and profit status of Systemic Idiopathic Juvenile Arthritis Treatment, and marketing status

Market growth drivers and challenges

The report segments the EMEA Systemic Idiopathic Juvenile Arthritis Treatment market as:

EMEA Systemic Idiopathic Juvenile Arthritis Treatment Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe  
Middle East  
Africa

EMEA Systemic Idiopathic Juvenile Arthritis Treatment Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Adalimumab Biosimilar  
Canakinumab  
Golimumab  
Tocilizumab Biosimilar  
Others

EMEA Systemic Idiopathic Juvenile Arthritis Treatment Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Clinic  
Hospital  
Others

EMEA Systemic Idiopathic Juvenile Arthritis Treatment Market: Players Segment Analysis (Company and Product introduction, Systemic Idiopathic Juvenile Arthritis Treatment Sales Volume, Revenue, Price and Gross Margin):

Alteogen Inc.  
Bristol-Myers Squibb Company  
Epirus Biopharmaceuticals, Inc.  
Johnson & Johnson  
Momenta Pharmaceuticals, Inc.  
Mycenax Biotech Inc.  
Novartis AG  
Oncobiologics, Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



## Contents

### **CHAPTER 1 OVERVIEW OF SYSTEMIC IDIOPATHIC JUVENILE ARTHRITIS TREATMENT**

- 1.1 Definition of Systemic Idiopathic Juvenile Arthritis Treatment in This Report
- 1.2 Commercial Types of Systemic Idiopathic Juvenile Arthritis Treatment
  - 1.2.1 Adalimumab Biosimilar
  - 1.2.2 Canakinumab
  - 1.2.3 Golimumab
  - 1.2.4 Tocilizumab Biosimilar
  - 1.2.5 Others
- 1.3 Downstream Application of Systemic Idiopathic Juvenile Arthritis Treatment
  - 1.3.1 Clinic
  - 1.3.2 Hospital
  - 1.3.3 Others
- 1.4 Development History of Systemic Idiopathic Juvenile Arthritis Treatment
- 1.5 Market Status and Trend of Systemic Idiopathic Juvenile Arthritis Treatment 2013-2023
  - 1.5.1 EMEA Systemic Idiopathic Juvenile Arthritis Treatment Market Status and Trend 2013-2023
  - 1.5.2 Regional Systemic Idiopathic Juvenile Arthritis Treatment Market Status and Trend 2013-2023

### **CHAPTER 2 EMEA MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA 2013-2017
- 2.2 Consumption Market of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA by Regions
  - 2.2.1 Consumption Volume of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA by Regions
  - 2.2.2 Revenue of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA by Regions
- 2.3 Market Analysis of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA by Regions
  - 2.3.1 Market Analysis of Systemic Idiopathic Juvenile Arthritis Treatment in Europe 2013-2017
  - 2.3.2 Market Analysis of Systemic Idiopathic Juvenile Arthritis Treatment in Middle East 2013-2017

2.3.3 Market Analysis of Systemic Idiopathic Juvenile Arthritis Treatment in Africa 2013-2017

2.4 Market Development Forecast of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA 2018-2023

2.4.1 Market Development Forecast of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA 2018-2023

2.4.2 Market Development Forecast of Systemic Idiopathic Juvenile Arthritis Treatment by Regions 2018-2023

## **CHAPTER 3 EMEA MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole EMEA Market Status by Types

3.1.1 Consumption Volume of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA by Types

3.1.2 Revenue of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA by Types

3.2 EMEA Market Status by Types in Major Countries

3.2.1 Market Status by Types in Europe

3.2.2 Market Status by Types in Middle East

3.2.3 Market Status by Types in Africa

3.3 Market Forecast of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA by Types

## **CHAPTER 4 EMEA MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA by Downstream Industry

4.2 Demand Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Downstream Industry in Major Countries

4.2.1 Demand Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Downstream Industry in Europe

4.2.2 Demand Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Downstream Industry in Middle East

4.2.3 Demand Volume of Systemic Idiopathic Juvenile Arthritis Treatment by Downstream Industry in Africa

4.3 Market Forecast of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF SYSTEMIC IDIOPATHIC**

## **JUVENILE ARTHRITIS TREATMENT**

5.1 EMEA Economy Situation and Trend Overview

5.2 Systemic Idiopathic Juvenile Arthritis Treatment Downstream Industry Situation and Trend Overview

## **CHAPTER 6 SYSTEMIC IDIOPATHIC JUVENILE ARTHRITIS TREATMENT MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EMEA**

6.1 Sales Volume of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA by Major Players

6.2 Revenue of Systemic Idiopathic Juvenile Arthritis Treatment in EMEA by Major Players

6.3 Basic Information of Systemic Idiopathic Juvenile Arthritis Treatment by Major Players

6.3.1 Headquarters Location and Established Time of Systemic Idiopathic Juvenile Arthritis Treatment Major Players

6.3.2 Employees and Revenue Level of Systemic Idiopathic Juvenile Arthritis Treatment Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 SYSTEMIC IDIOPATHIC JUVENILE ARTHRITIS TREATMENT MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Alteogen Inc.

7.1.1 Company profile

7.1.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product

7.1.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Alteogen Inc.

7.2 Bristol-Myers Squibb Company

7.2.1 Company profile

7.2.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product

7.2.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company

7.3 Epirus Biopharmaceuticals, Inc.

7.3.1 Company profile

- 7.3.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product
- 7.3.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Epirus Biopharmaceuticals, Inc.
- 7.4 Johnson & Johnson
  - 7.4.1 Company profile
  - 7.4.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product
  - 7.4.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 7.5 Momenta Pharmaceuticals, Inc.
  - 7.5.1 Company profile
  - 7.5.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product
  - 7.5.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Momenta Pharmaceuticals, Inc.
- 7.6 Mycenax Biotech Inc.
  - 7.6.1 Company profile
  - 7.6.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product
  - 7.6.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Mycenax Biotech Inc.
- 7.7 Novartis AG
  - 7.7.1 Company profile
  - 7.7.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product
  - 7.7.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Novartis AG
- 7.8 Oncobiologics, Inc.
  - 7.8.1 Company profile
  - 7.8.2 Representative Systemic Idiopathic Juvenile Arthritis Treatment Product
  - 7.8.3 Systemic Idiopathic Juvenile Arthritis Treatment Sales, Revenue, Price and Gross Margin of Oncobiologics, Inc.

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF SYSTEMIC IDIOPATHIC JUVENILE ARTHRITIS TREATMENT**

- 8.1 Industry Chain of Systemic Idiopathic Juvenile Arthritis Treatment
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF SYSTEMIC IDIOPATHIC JUVENILE ARTHRITIS TREATMENT**

- 9.1 Cost Structure Analysis of Systemic Idiopathic Juvenile Arthritis Treatment
- 9.2 Raw Materials Cost Analysis of Systemic Idiopathic Juvenile Arthritis Treatment
- 9.3 Labor Cost Analysis of Systemic Idiopathic Juvenile Arthritis Treatment
- 9.4 Manufacturing Expenses Analysis of Systemic Idiopathic Juvenile Arthritis Treatment

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF SYSTEMIC IDIOPATHIC JUVENILE ARTHRITIS TREATMENT**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference



## I would like to order

Product name: Systemic Idiopathic Juvenile Arthritis Treatment-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/S7988792B7FEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S7988792B7FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

